From Grafa:
Paradigm Biopharmaceuticals is currently conducting a global, Phase 3 clinical trial for its iPPS treatment for osteoarthritis (OA).In this interview, Paradigm Biopharmaceuticals Managing Director Paul Rennie discusses the potential for the company’s breakthrough treatment to break into the $8.28 billion global market for osteoarthritis therapeutics. Paradigm has cashed up, having raised $30.1 million in October last year to develop its iPPS treatment for the disease.
https://grafa.com/news/paradigm-biopharmaceuticals--asx-par--conducting-phase-3-osteoarthritis-trial-179958
Video: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.010(3.51%) |
Mkt cap ! $96.19M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 27.0¢ | $45.01K | 159.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17942 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 9634 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
27.5¢ |
Change
-0.010 ( 3.51 %) |
||||
| Open | High | Low | Volume | ||
| 29.0¢ | 29.0¢ | 27.0¢ | 41613 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| PAR (ASX) Chart |